Lion Corporation (JP:4912)
:4912
Want to see JP:4912 full AI Analyst Report?
Top Page
Lion
(4912)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥1,616.00
▼(-3.29% Downside)
Action:Downgraded
Date:05/14/26
The score is driven primarily by solid financial performance (improving margins and low leverage), partially offset by weak technicals (price below key moving averages with negative momentum) and a somewhat high P/E relative to the modest dividend yield.
Positive Factors
Improving profitability
Meaningful margin recovery versus 2023 implies better pricing, cost control and product mix. Sustained higher margins materially increase persistent operating cash generation, support reinvestment in R&D/marketing and improve resilience to input-cost swings over the next several quarters.
Negative Factors
Modest revenue growth
Very slow top-line expansion constrains scale economies and limits the firm’s ability to grow absolute earnings quickly. Over several quarters, modest top-line momentum increases reliance on margin gains to deliver earnings growth and raises execution risk for market-share recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving profitability
Meaningful margin recovery versus 2023 implies better pricing, cost control and product mix. Sustained higher margins materially increase persistent operating cash generation, support reinvestment in R&D/marketing and improve resilience to input-cost swings over the next several quarters.
Read all positive factors
Lion (4912) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥428.00B
Dividend Yield1.73%
Average Volume (3M)1.11M
Price to Earnings (P/E)27.4
Beta (1Y)0.40
Revenue Growth3.10%
EPS Growth27.99%
CountryJP
Employees7,654
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)100.37
Shares Outstanding279,782,750
10 Day Avg. Volume1,063,460
30 Day Avg. Volume1,106,010
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.41
Price to Sales (P/S)1.08
P/FCF Ratio20.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,068.75Price Target Upside23.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)92.96
Revenue Forecast (FY)¥431.00B
Lion Business Overview & Revenue Model
Company Description
Lion Corporation manufactures and sells consumer and industrial products in Japan and internationally. It operates through three segments: Consumer Products Business, Industrial Products Business, and Overseas Business. The company offers dental a...
How the Company Makes Money
Lion Corporation generates revenue primarily through the sale of its consumer products, including oral care items, such as toothpaste and toothbrushes; beauty and personal care products; and household cleaning agents, including detergents and fabr...
Lion Earnings Call Summary
Earnings Call Date:Nov 07, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted an increase in net sales and profits, driven by effective price revisions and structural reforms. However, challenges such as impairment losses, a decline in domestic sales, and a slowdown in certain overseas markets were also noted. The partnership with Japan Activation Capital is a strategic move to bolster future growth.Positive Updates
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Negative Updates
Impairment Loss on Domestic Facilities
Impairment loss of approximately JPY 6.2 billion due to streamlining of domestic home care production facilities.
Read all updates
Q3-2024 Updates
Positive
Negative
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Read all positive updates
Company Guidance
In the earnings call for Q3 2024, Lion Corporation reported a 1.7% increase in net sales to JPY 301.1 billion, with a core operating income rise of JPY 6 billion year-on-year, reaching JPY 18.6 billion. The EBITDA was JPY 32.5 billion, up by JPY 6.4 billion, with a margin increase of 2 percentage points to 10.8%. Despite an impairment loss of JPY 6.2 billion due to domestic production facility streamlining, the company maintained its full-year forecast, attributing the resilient performance to price revisions and cost reductions, specifically mentioning a JPY 2.8 billion price revision impact and a total cost reduction of JPY 2.2 billion. The consumer product sales in Japan fell by 4.3%, whereas overseas sales showed sustained double-digit growth. The company plans further asset sales in Q4 to support ongoing structural reforms, aiming for a total shareholder return ratio of 91.9% with a dividend set at JPY 27 per share.Lion Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
69
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.06B | 422.09B | 412.94B | 402.77B | 389.87B | 366.23B |
| Gross Profit | 197.68B | 193.92B | 188.78B | 180.60B | 174.61B | 179.10B |
| EBITDA | 53.22B | 51.89B | 46.76B | 39.63B | 40.88B | 44.93B |
| Net Income | 27.77B | 27.59B | 21.20B | 14.63B | 21.94B | 23.76B |
Balance Sheet | ||||||
| Total Assets | 520.31B | 528.60B | 497.17B | 486.36B | 469.28B | 428.02B |
| Cash, Cash Equivalents and Short-Term Investments | 57.56B | 88.09B | 102.24B | 85.53B | 101.08B | 97.25B |
| Total Debt | 40.77B | 54.44B | 29.74B | 30.34B | 32.17B | 8.37B |
| Total Liabilities | 170.60B | 180.17B | 181.47B | 188.23B | 190.11B | 163.01B |
| Stockholders Equity | 323.16B | 322.73B | 293.72B | 280.32B | 264.25B | 251.57B |
Cash Flow | ||||||
| Free Cash Flow | 23.85B | 22.57B | 25.60B | 6.34B | 23.47B | -17.99B |
| Operating Cash Flow | 39.95B | 40.65B | 43.66B | 30.07B | 41.96B | 19.30B |
| Investing Cash Flow | -55.90B | -43.37B | -7.19B | -34.37B | -19.54B | -34.18B |
| Financing Cash Flow | -9.20B | -12.50B | -21.67B | -12.19B | -19.82B | -10.22B |
Lion Technical Analysis
Positive
1671.00
Price Trends
1631.67
Negative
1669.78
Negative
1614.83
Positive
Market Momentum
-20.70
Negative
57.74
Neutral
84.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4912, the sentiment is Positive. The current price of 1671 is above the 20-day moving average (MA) of 1571.45, above the 50-day MA of 1631.67, and above the 200-day MA of 1614.83, indicating a neutral trend. The MACD of -20.70 indicates Negative momentum. The RSI at 57.74 is Neutral, neither overbought nor oversold. The STOCH value of 84.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4912.
Lion Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥590.96B | 15.88 | 12.66% | 1.53% | 11.37% | 11.35% | |
69 Neutral | ¥298.83B | 196.80 | 2.72% | 2.61% | 1.63% | 74.87% | |
65 Neutral | ¥439.42B | 105.71 | 5.37% | 1.95% | 3.14% | -71.37% | |
65 Neutral | ¥1.73T | 20.40 | 10.79% | 3.47% | -2.89% | -31.75% | |
64 Neutral | ¥428.00B | 27.36 | 9.09% | 1.73% | 3.10% | 27.99% | |
64 Neutral | ¥2.68T | 22.54 | 11.50% | 2.41% | 3.60% | 13.80% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
JP:4912
Lion
1,577.00
28.71
1.85%
JP:4452
Kao
5,919.00
-201.11
-3.29%
JP:4967
Kobayashi Pharmaceutical Co
5,925.00
996.52
20.22%
JP:4922
Kose
5,238.00
-72.95
-1.37%
JP:4527
Rohto Pharmaceutical Co
2,545.50
478.21
23.13%
JP:8113
Unicharm
948.50
-164.05
-14.75%
Lion Corporate Events
Lion lifts Q1 profit on high value-added oral care push, keeps 2026 outlook
May 12, 2026
Lion Corporation reported that first-quarter 2026 net sales rose 5.3% year on year to ¥99.20 billion, with core operating income up 13.8% to ¥6.01 billion and an EBITDA margin of 11.1%, driven by a shift to higher value-added oral care p...
Lion Corporation Delivers Strong Q1 2026 Earnings and Confirms Full-Year Outlook
May 12, 2026
Lion Corporation reported solid first-quarter 2026 results, with net sales rising 5.3% year on year to ¥99.2 billion and operating profit climbing 11.6% to ¥6.3 billion, supported by a 13.8% increase in core operating income. Profit attr...
Lion to Book ¥15.9 Billion Extraordinary Gain From Sale of Chemical Subsidiaries
Feb 16, 2026
Lion Corporation will record an estimated ¥15,953 million in extraordinary income on a non-consolidated basis from the transfer of all shares in two consolidated subsidiaries in its chemical products business. The gain arises from the sale of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.